Meiji Seika Pharma Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Meiji Seika Pharma Co., Ltd
US FDA closed out the month of April with two new molecular entity approvals that address underserved markets but carry some safety concerns.
Japan struggles to recover its ever-expanding supply chain for generic drugs after several key players had their production stopped because of a series of GMP violations. As the share of generics grows under government policy, some in the industry argue the problems are deeply rooted in a decades-old pricing system.
Intas has secured a distributor for its ranibizumab biosimilar throughout select countries in the Middle East, while Phase III trials continue ahead of anticipated US approval.
Phase III data showed that the first-in-class oral antifungal can prevent recurrence of vaginal yeast infections, a potentially valuable label addition to the current indication for acute treatment.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Chemo-Sero Therapeutic Research Institute of Japan
- Meiji Holdings
- Meiji Seika Kaisha
- KM Biologics Co., Ltd.
- Romeck Pharma, LLC
- Meiji Pharma USA Inc.